|Articles|June 1, 2006

C1 inhibitors opening doors

C1-INH treatment shortened the mean duration of abdominal attacksfrom 92 to 40 hours and the mean maximal pain score declined from8.6 to 4.5.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!

Related Content

Patrick Burnett, MD, PhD, Outlines Arcutis' Pediatric Strategy for Roflumilast in AD and Psoriasis

ByMarie Bosslett, Assistant Editor,Patrick Burnett, MD, PhD

December 1st 2025

Bridging the Literacy Gap to Strengthen Dermatologic Care

ByKen Korber, PA-C, MHPE, DFAAPA,Kaitlyn Bader, Assistant Managing Editor

November 21st 2025

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years

ByMarie Bosslett, Assistant Editor

November 17th 2025

Advancing Topical Stewardship and Expanding Nonsteroidal Options

ByPeter Lio, MD,Kaitlyn Bader, Assistant Managing Editor

November 14th 2025

Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream for Infant AD

ByMarie Bosslett, Assistant Editor

November 13th 2025

Latest CME

Video

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Video

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Multimedia

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Register now!

Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Video

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Multimedia

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

C1 inhibitors opening doors

Newsletter

Related Content

Patrick Burnett, MD, PhD, Outlines Arcutis' Pediatric Strategy for Roflumilast in AD and Psoriasis

Bridging the Literacy Gap to Strengthen Dermatologic Care

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years

Advancing Topical Stewardship and Expanding Nonsteroidal Options

Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream for Infant AD

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Trending on Dermatology Times

JAK Inhibitors Show Comparable Safety to TNF Antagonists

First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC

Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1

Phase 2 Nemolizumab Trial Opens for CPUO